Across 96 Phase II/III gastric, gastroesophageal, and esophageal cancer trial records, site activity is concentrated in recurring EU oncology hubs rather than evenly distributed across countries. Phase II represented 64 of 96 records (66.7%), while Germany, France, Spain, and Italy together formed the dominant country allocation pool, led by Germany with 2,778 participant allocations among the top four countries.
The top 10 named EU sites account for 69 high-frequency trial-site records. Hospital Universitari Vall d’Hebron ranks first with 10 records, followed by Institut Gustave Roussy and Hospital General Universitario Gregorio Marañón with 8 records each.
The active-site pattern is anchored by large academic oncology centers and high-throughput GI oncology networks. Spain, France, Germany, Belgium, Italy, and Sweden all contribute recurring hubs, suggesting that upper GI cancer development depends on a pan-European core rather than a single-country site model.
Among the four largest country allocation pools, Germany accounts for 2,778 of 7,283 participant allocations (38.1%), followed by France with 2,000 (27.5%), Spain with 1,585 (21.8%), and Italy with 920 (12.6%).
Germany shows the strongest allocation footprint, driven by repeated large country records in both Phase II and Phase III. France follows closely, while Spain combines strong participant allocation with high individual-site recurrence, making it operationally important even when not the largest country by allocated participants.
Phase II trials account for 64 of 96 records (66.7%), while Phase III trials account for 32 of 96 records (33.3%). This means the site landscape is shaped more by mid-stage expansion and signal-seeking studies than by late-stage confirmatory programs alone.
The operational center of gravity sits in Phase II. For sponsors, this makes early site-network selection especially important: the same high-frequency sites can become strategic bridges into later Phase III execution.
Most records are concentrated in 2024: 61 of 96 records (63.5%). Activity then decreases to 27 of 96 records in 2025 (28.1%) and 8 of 96 records in 2026 (8.3%).
The dataset is heavily weighted toward 2024-authorized records, which means the observed active-site pattern reflects established network choices more than a narrow snapshot of only newly emerging 2026 programs.
Upper GI cancer trial activity is concentrated in a recurring European network of academic oncology centers, GI-focused cancer units, and high-volume national trial systems. The strongest site-level signal is not isolated country dominance, but repeated reuse of specialized centers across Phase II and Phase III development.
For upper GI oncology development, the most efficient European site strategy appears to combine large national allocation pools in Germany and France with recurrent high-performance centers in Spain, Italy, Belgium, and Sweden. This pattern supports a hub-and-network model: anchor the study in countries with large participant allocations, then reinforce execution through recurring disease-specialist sites.